Cancer Genetics — IPO Roadshow (August 2013)
36 slides from Cancer Genetics's IPO roadshow presentation, Aug 5, 2013
Slide 1: Issuer Free Writing Prospectus
Issuer Free Writing Prospectus Filed pursuant to Rule 433 Registration No. 333-189117 August 5, 2013 August 5, 2013 TREATMENT CANCER PERSONALIZED EMPOWERING
Slide 2: Forward-Looking Statements
Forward-Looking All products Any considered Forward-looking clinical Form Actual The business. statements Company statements S-1 results trials and and toservices, or be other may disclaims pertaining that regulatory forward-looking statements Statement differ reports arealong not any materially toa
Slide 3: Free Writing Prospectus legend
Freehave This We Before complete You http://www.sec.gov. Avenue, may Writing presentation you 18th filed get information invest, these Prospectus Floor, a registration highlights you documents Alternatively, New about should Statement York, statement us basic for read and NY free information we the
Slide 4: Offering Summary
Issuer Exchange Offering Over-Allotment Fully Sales Mayo Product Use Continued General Sole Co-Lead *Share 2013 of Book-Runner Cancer and Diluted Clinic Cancer Proceeds numbers Commercialization Working Summary Size Manager Marketing OTCQB R&D Joint Genetics, Shares $15,000,000 Genetics, 15% are Ret
Slide 5: Growth-Stage, Hybrid Portfolio
Growth-Stage, Hybrid Portfolio 54% Experienced Category Established stablished ü 2013 Hybrid Portfolio 54% Experienced Category Established revenue Cancer revenue business of business continues multi-year of continues multi-year collaborations commercially management Genetics, growth collaborations
Slide 6: Our Molecular Diagnostic Approach
Molecular Our DIAGNOSIS Use provide and of Do what Integrated PATIENTS oncology PHYSICIANS an PAYORS first PHARMA require 2013 the informed Idefinitive unique genomics time, have type? Cancer cancer companion ancare Benefit and cancer Molecular Diagnostics See accurate prospects? Receive focus treat
Slide 7: Situation and CGI's Success
Situation CGI’s Success Traditional Phenotypic Physical Morphologic Pathological Large Specimens Significant Treatment & Mission Rate Multiple Examination Today Treatment Required Approach Delays &Analysis & inBiomarkers isGenomic Cancer Target to Reduced toPersonalize Number Plans Improved Our Prop
Slide 8: Unique, Proprietary Products and Services
Unique, PROPRIETARY Proprietary Clinically Sold IP-protected Probe Differentiated Superior Serving Biomarker World-class Drug-specific Comprehensive Suite 2013 globally Cancer of manufacturing community Products Scalable turnaround validated and molecular expertise genomics Genetics, and companion f
Slide 9: Our Target Markets
Our Lymphoma, Hematological: 149,990 Source: 36% Kidney, Urogenital: 376,310 Cervical, Gynecological: 84,140 Death (U.S.) 5 Ability 2013 Products Target Estimated Cancer Rate to American Bladder Endometrial Impact Launched Markets 16% 31% Leukemia, Genetics, New &Over Cancer Prostate inCases in& Onc
Slide 10: Proprietary Products
5 Proprietary Commercially Research Discovery MatBA®—Chronic MatBA®—Diffuse MatBA®—Mantle FHACT”- FHACT”—Cervical* UroGenRA”-Prostate UroGenRA”—Bladder UroGenRA”—Kidney MatBA®—MM MatBA®—FL Clinical UGenRA”—Ovarian UGenRA”—Endometrial UGenRA”—Cervical 2013 Cancer Collaboration &Head&Neck*—Launched De
Slide 11: Hematologic Cancers
Despite Identified (US Genomics-Based 2013Only, Cancer Improved Leukemia perGenetics, 100,000) Tests Cancer & Inc. like Lymphoma Care, MatBA® | OTCQB: Case Subtypes Numbers are CGIX Critical Incidence |11forand Hematologic Improve & Survival the Cancers Management Rates are for Still NHLsand Rising
Slide 12: MatBA-CLL/SLL Impact
MatBA®-CLL/SLL Impact FISH (Current 38% Favorable Unfavorable Favorable/ (no Intermediate 8% 15% caught Genomic by 4 Validated Additional 2013 20FISH: distinction) of of 23% Cancer clinical cases using on cases Method)(CGI Aberrations by in prognosis therapy Validations 85% with Collaboration MatBA®
Slide 13: MatBA-CLL/SLL Risk Stratification
MatBA® MatBA®- Poor Intermediate Detection ü -Free GOOD Time Overall Surviving P Proportion _ Being 20 Patients Provides P GOOD INTERMED POOR < =0.010 = 0.090 0.001 key outcome to (months) 0.001 Treatment Leukemia 2013 (n=74) Survival First actively (n=47) genetic Cancer(n=74) Can of classified CLL
Slide 14: UroGenRA-Kidney
UroGenRA”-Kidney PROBLEM Men often nephrectomy and Prospective Retrospective In-silico Subtype n pRCC Clinical 2013 Approaching Test Tested Demonstrated J. Coleman experience and Cancer undergo to (n=75) Benefits Specificity to validation distinguish women subtype ongoing SOLUTION Genetics, for (MSK
Slide 15: FHACT-Cervical
Genomic FHACT”— Cervical 90% HPV+ to Abnormal Decreased Provides Predicts Normal Regress the cancer critical Amplification Grade Risk A progression 10% Neweffects for information Cervical Progress Cancer Genomic nearly By and toLesions Disease associated Higher which Aid 500,000 InIncreased reduces
Slide 16: IP and Patent Portfolio
IPUS Panel Tool Methods n Strong IP-based Validation Filing 2013 Position for Cancer 11/932,422 Issued 61/581,350 12/980,480 13/227,027 for and and Diagnosis on of and for the maintenance of growing and Analyzing unique Patent Detecting Genetics, Detection Tools specific Detailed n and Europe US 7,5
Slide 17: Commercialization Strategy
Large, Target Universities Community Biotechnology Emerging n 2013 Commercialization Collaborate Continue Leverage Expand Enhance Cancer Markets Targeted sales Markets distributor to clinical Hospitals and Genetics, to growing Companies emphasis Market create Research infrastructure Strategy base Re
Slide 18: Community Hospital Opportunity
Unique Expanding 4,000 & 85% Initially Hospitals $600,000—$800,000 Opportunity n 2013 Allows Delivers Enables Brings Improving CFOs Laboratories Of Cancer toService All Diagnosed 5,000 personalized community &community better &U.S. Laboratories on care Genetics, Developing Community in Average Offer
Slide 19: Clinical Trial Services for Oncology Drugs
Clinical ONCOLOGY 55% GROWTH CLIENTS 1H, $221 $684 Source: Well-Positioned 20132011 21% Cancer Company Trial 1H, 2011 ($000) INGenetics, Services 2012 DRUGS CGI’s 2016 for $1,738 Analysis 1H, Use DIRECT Showing Inc. ASSOCIATED 2013 in Clinical |and OTCQB: BILL Management Strong Trials CGIX WITH Grow
Slide 20: Gilead Relationship Highlights
n Comprehensive, Highlights occur and The CGI’s potential Gilead across SelectRelationship several One” outcomes biomarker-based Offering methodologies, nGilead Exemplifies Trials cover is Currently patient including the bothSignificant national profiling Using flowaand cytometry, Comprehensive will
Slide 21: Collaborations Driving Product Adoption
Collaborations Leading n RenalVenture Joint DLBCL CLL Cervical Cancer, Differentiated Cancer with Focused DLBCL, &Premier DLBCL Research onMCL Oncology Cancer n Cervical &&FL Driving Research & Next Cancer Product Generation Institutions n Kidney Adoption Sequencing Cancer n DLBCL, Head & Neck Cance
Slide 22: International Distribution Partnerships
Well-Positioned n We International Expect Expanded Continued focus exposure our distribution focus revenue efforts and on toGrowing increase increasing through comes network Internationally to from partnerships international emerging with sale 4 new of economies oncology todistributors Including par
Slide 23: Roche Servicios Partnership
Alvaro CGI n Highlights and development “Since time CGI CGIX 2013processed will towon the Soto, our bebeginning, Cancer Press patients. aproviding Roche global ton expand CGIRFP Release: Servicios This Genetics,interacts CGI genomic the to commitment Cancer Inc. understood relationship |help |with C
Slide 24: Mayo Clinic Joint Venture, OncoSpire
Mayo Investing Next Highlights CGI n The CGIX 2013 JVValue Mayo commits to Generation Cancer Clinic Press develop commits inand the Release: Joint Genetics, up Focus Future clinical Sequencing to toVenture $6 “in-kind” of Mayo MInc. –diagnostic Next OncoSpire over |Clinic OTCQB: in Generation servic
Slide 25: Strong Revenue History of Growth
Strong CGI Total $3.02 $4.30 $1.67 $2.52 Clinical 3,622 5,115 6,610 2009 2,321 Trailing 2013 Revenue 2010 Cancer Revenue $3.05 3,146 History Volume 12 2011 Months Genetics, &($Mn) of2012 (Tests Clinical Growth Revenue 1H-2013 Inc. Processed) Volume | OTCQB: is $5.4 Trends Mn CGIX (2009 | 25 – 2013 t
Slide 26: Quarterly Revenue Growth
Strong (Quarterly Total * Note: $10K Q1,2012: 2nd $185K Q2,2012: Grants Excluding 2013 Grants Quarter Cancer Revenue Approx. History Grants Comparison 2013 Genetics, 90% ($000) of Growth—Revenue vs.Growth 2012, Clinical Inc. 2012| OTCQB: vs. Volume 2013)&CGIX (Tests Clinical |Processed) 26Volume Tre
Slide 27: Summary Income Statement
Summary (2009-2013 Income Revenue Research Sales (Loss) $ 2013 in thousands Cancer &(7,328) Statement Marketing $1,666 &Statement thru Development Genetics, (8,407) 2009—2012 $2,522 6 Item mos) (S&M) of(19,887) Inc. Operations 2009 $3,019 (R&D) 239 |audited OTCQB: 2010 716 $4,302 (6,666) 1,336 2011
Slide 28: Summary Quarterly Income Statement
Summary (Quarterly Income Revenue Gross Research Loss $ 2013 in thousands From Cancer Profit Statement $1,148 &Statement &Operations Development 62 Genetics, First 553 $1,832 Item Half +100% of(2,234) Inc. Operations Comparisons Q2 60%(R&D) 2012 |74 OTCQB: $1,983 (1,734) 701 Q2 527 +100% 2013 $3,050
Slide 29: Additional Gross Profit Improvement Initiatives
Consistent Additional Gross Highlights n 2013 Manufacturing Increased Process Capacity Leveraging Developing Cancer Profit improvement of Focus Efforts utilization automation Margin Genetics, cloud Initiatives innovative in on Focused India for Gross Inc. scale and model (Probes) Profit |Operational
Slide 30: Diversified Revenue Mix
Multiple Payor Selected Reimbursement Insurance & Medicare 2013 Care Cancer Revenue Facilities Payors Customer Grants, Companies Genetics, Mix Based Royalty Types 2013 Companies, Direct Inc.Provide (1H, &| OTCQB: Other Bill 2013) /Diversified Hospitals PayCGIX Based| Revenue 30 Mix With Covered Live
Slide 31: Experienced Board and Officers
Experienced Board Officers Raju 35 Major Panna 15+ Founded Elizabeth 9 JPMorgan, Jane 25 Published NIH Scientific Andrea Chairman Timothy Riccardo Hans-Guido Principal Vundavalli Director, Andrew Chief 2013 yrs years years Houldsworth, grantee Chaganti, as Cancer Strategy of ofCalifano, discoveries
Slide 32: Recent Accomplishments and Upcoming Milestones
Strong, Recent MCL ü Upcoming n 2013 Accelerating Additional Announcing Received Finalized Launched Increasing Launching UroGenRA™ MatBA® CE Approval Cancer (Mantle Accomplishments Commercially-Focused Milestones Agreement CLIA –OncoSpire UroGenRA™ FHACT™ covered international news multi-marker Gene
Slide 33: For further information, please contact us
For further Cancer Meadows www.cancergenetics.com Genetics, Office information, Complex Inc. please 201 contact Route 17usNorth at [email protected] Rutherford, NJ 07070 (201) 528-9200
Slide 34: Appendix
I. CGIX Appendix II. DNA Capitalization Detection Methodologies Table Utilized By CGI
Slide 35: Summary Capitalization Table
I. Summary CGIX Common Warrants* Total Excludes 440,390 * 2013 –Cap Fully Some options 450,390: Stock –Table Cancer Capitalization Average Diluted of4,316,691 reserved the As warrants of Genetics,Exercise Pre-Offering 06/30/2013 for Inc.Table future have Price6,750,778 | OTCQB: anti-dilution issuanc
Slide 36: DNA Detection Methodologies Utilized by CGI
II. Expanding DNA-FISH Low Mid-High Existing High Low-Mid Value: Natural DNA Very The Emerging Step 2013 Next •Resolution High Resolution Cancer Microarray Next Value: High Growing Extension CGI Market Market Resolution Generation Probe in Genetics, High Capabilities Proprietary established in (~1-2